Details for New Drug Application (NDA): 018450
✉ Email this page to a colleague
NDA 018450 describes NITROPRESS, which is a drug marketed by Abbott, Abbvie, Hospira, and Vpna, and is included in four NDAs. Additional details are available on the NITROPRESS profile page.
The generic ingredient in NITROPRESS is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.
The generic ingredient in NITROPRESS is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.
Summary for 018450
| Tradename: | NITROPRESS |
| Applicant: | Abbvie |
| Ingredient: | sodium nitroprusside |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
